537
Views
13
CrossRef citations to date
0
Altmetric
ART

A randomized controlled trial of the GnRH antagonist ganirelix in Chinese normal responders: high efficacy and pregnancy rates

, , , , , , , & show all
Pages 800-804 | Received 08 Jun 2011, Accepted 06 Feb 2012, Published online: 20 Mar 2012

References

  • Lau JT, Wang Q, Cheng Y, Kim JH, Yang X, Tsui HY. Infertility-related perceptions and responses and their associations with quality of life among rural Chinese infertile couples. J Sex Marital Ther 2008;34:248–267.
  • Heng BC. Stringent regulation of oocyte donation in China. Hum Reprod 2009;24:14–16.
  • International Committee for Monitoring Assisted Reproductive Technology (ICMART). World collaborative report on assisted reproductive technology. Hum Reprod 2009;1:1–11.
  • Tan F, Wang J. Evaluation of development of assisted reproductive technology. J China Med Univ 2009;38:154–156.
  • Devroey P, Aboulghar M, Garcia-Velasco J, Griesinger G, Humaidan P, Kolibianakis E, Ledger W, et al. Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. Hum Reprod 2009;24:764–774.
  • Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333–340.
  • Chen SL, Yin MN, Sun L, Li H, Chen X, Song HD, He JX, et al. Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer. Nan Fang Yi Ke Da Xue Xue Bao 2007;27:588–590.
  • Li QH, Quan S, Chen LN, Li H, Gao RH, Ni H, Yu M, et al. Analysis of the clinical outcomes of 160 patients undergoing repeated IVF/ICSI-ET treatment. Nan Fang Yi Ke Da Xue Xue Bao 2010;30:236–238.
  • Lin YH, Wen YR, Chang Y, Seow KM, Hsieh BC, Hwang JL, Tzeng CR. Safety and efficacy of mixing cetrorelix with follitropin alfa: a randomized study. Fertil Steril 2010;94:179–183.
  • Zhen X, Qiao J, Li R, Ma C, Lui P. The application of gonadotropin-releasing hormone antagonist on the patients with poor ovarian response. Chin J Birth Health Hered 2009;17:118–120.
  • Ye H, Huang GN, Zeng PH, Pei L. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study. J Assist Reprod Genet 2009;26:105–111.
  • Butts SF, Seifer DB. Racial and ethnic differences in reproductive potential across the life cycle. Fertil Steril 2010;93:681–690.
  • Purcell K, Schembri M, Frazier LM, Rall MJ, Shen S, Croughan M, Grainger DA, Fujimoto VY. Asian ethnicity is associated with reduced pregnancy outcomes after assisted reproductive technology. Fertil Steril 2007;87:297–302.
  • Gleicher N, Weghofer A, Li J, Barad D. Differences in ovarian function parameters between Chinese and Caucasian oocyte donors: do they offer an explanation for lower IVF pregnancy rates in Chinese women? Hum Reprod 2007;22:2879–2882.
  • Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665–1677.
  • Landis RJ, Heyman ER, Koch GG. Average partial association in three-way contingency tables: a review and discussion of alternative tests. Int Statist Rev 1978;46:237–254.
  • Corifollitropin Alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online 2010;21:66–76.
  • The European Orgalutran Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490–1498.
  • Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, et al.; North American Ganirelix Study Group. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38–45.
  • Rombauts L, Healy D, Norman RJ; Orgalutran Scheduling Study Group. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 2006;21:95–103.
  • The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;1:644–651.
  • Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651–671.
  • Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063–3072.
  • Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online 2007;14:640–649.
  • Al-Inany H, Aboulghar MA, Mansour RT, Serour GI. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online 2005;10:567–570.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.